Evaluation of Critical Formulation Factors in the Development of a Rapidly Dispersing Captopril Oral Dosage Form

References

• Seager H. Drug delivery products and the Zydis fast dissolving dosage form. J. Pharm. Pharmacol 1998; 50(4)375–382
   PubMed Web of Science ®Google Scholar
• Johannessen T., Kristensen P. On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast dissolving famotidine wafers and ranitidine tablets. Clin. Ther. 1997; 19(1)73–81
   PubMed Web of Science ®Google Scholar
• The fifth report of the joint national committee on detection, evaluation, and treatment of high hlood pressure (JNC V). Arch. Intern. Med. 1993; 153(2)154–183
   PubMed Web of Science ®Google Scholar
• Nur A.O., Zhang J.S. Recent progress in sustained/controlled oral delivery of captopril: an overview. Int. J. Pharm. 2000; 194(2)139–146
   PubMed Web of Science ®Google Scholar
• Ohman K.P., Kagedal B., Larsson R., Kalberg E.B. Pharmacokinetics of captopril and its effect on blood pressure during acute and chronic administration and in relation to food intake. J. Cardiovasc. Pharm. 1985; 7: S20–S24
   PubMed Web of Science ®Google Scholar
• Ceyhan B., Karaaslan Y., Caymaz O., Oto A., Oram E., Oram A., Ugurlu S. Comparison of sublingual captopril and sublingual nifedifine in hypertensive emergencies. Jpn. J. Pharmacol. 1990; 52: 189–193
   PubMedGoogle Scholar
• Angeli P., Chiesa M., Caregaro L., Merkel C., Sacerdoti D., Rondana M., Gatta A. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. Arch. Intern. Med. 1991; 151: 678–682
   PubMed Web of Science ®Google Scholar
• Karachalios G.N., Chrioskos N., Kintziou H., Perogianopouos K., Kehagioglow K. Treatment of hypertensive crisis with sublingual captopril. Curr. Ther. Res. 1990; 48(1)5–9
   Web of Science ®Google Scholar
• Haude M., Steffen W., Erbel R., Meyer J. Sublingual administration of captopril versus nitroglycerin in patients with severe heart failure. Int. J. Cardiology 1990; 27: 351–359
   PubMed Web of Science ®Google Scholar
• Al-Furaih T.A., McElnay J.C., Elborn J.S., Rusk R., Scott M.G., McMahon J., Nicholls D.P. Sublingual captopril—a pharmacokinetic and pharmacodynamic evaluation. Eur. J. Clin. Pharmacol. 1991; 40: 393–398
   PubMed Web of Science ®Google Scholar
• McElnay J.C., Al-Furaih T.A., Hughes C.M., Scott M.G., Nicholls D.P. A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure. Eur. J. Clin. Pharmacol. 1996; 49(6)471–476
   PubMed Web of Science ®Google Scholar
• Kearney P., Wong S.K. Method for Making Freeze Dried Drug Dosage Forms. US Patent 5,631,023, May 20, 1997
   Google Scholar
• Green R., Kearney P. Process for Preparing Fast Dispersing Solid Oral Dosage Form. US Patent 5,976,577, November 2, 1999
   Google Scholar
• Mizumoto T., Masuda Y., Fukui M. Intrabuccally Dissolving Compressed Moldings and Production Process Thereof. US Patent 5,576,014, November 19, 1996
   Google Scholar
• Dijkgraaf B.L.J., Muhlenbruch A. Granulate for the Preparation of Fast-Disintegrating and Fast-Dissolving Compositions Containing A High Amount of Drug. US Patent 5,837,292, November 17, 1998
   Google Scholar
• Khankari R.K., Hontz J., Chastain S.J., Katzner L. Rapidly Dissolving Robust Dosage Form. US Patent 6,024,981, February 15, 2000
   Google Scholar
• Pather S.I., Robinson J.R., Eichman J.D., Khankari R.K., Hontz J., Gupte S.V. Effervescent Drug Delivery System for Oral Administration. US Patent 6,391,335, May 21, 2002
   Google Scholar
• Fuisz R.C. Rapidly Dispersible Compositions Containing Polydextrose. US Patent 5,501,858, March 26, 1996
   Google Scholar
• Myers G.L., Battist G.E., Fuisz R.C. Process and Apparatus for Making Rapidly Dissolving Dosage Units and Product Therefrom. US Patent 5,866,163, February 2, 1999
   Google Scholar
• Sachs E.M., Haggerty J.S., Cima M.J., Williams P.A. Three-Dimensional Printing Techniques. US Patent 5,204,055, April 20, 1993
   Google Scholar
• Cima M.J., Sachs E., Cima L.G., Yoo J., Khanuja S., Borland S.W., Wu B., Giordano R.A. Computer-derived microstructures by 3D printing: Bio- and Structural Materials. Solid Freeform Fabrication Symposium Proceedings. Univ. of Texas, 1994; 181–190
   Google Scholar
• Wu B.M., Borland S.W., Giordano R.A., Cima L.G., Sachs E.M., Cima M.J. Solid freeform fabrication of drug delivery devices. J. Control. Release 1996; 40: 77–87
   Web of Science ®Google Scholar
• Katstra W.E., Palazzolo R.D., Rowe C.W., Giritlioglu B., Teung P., Cima M.J. Oral dosage forms fabricated by three dimensional printing. J. Control. Release 2000; 66(1)1–9
   PubMed Web of Science ®Google Scholar
• Rowe C.W., Katstra W.E., Palazzolo R.D., Giritlioglu B., Teung P., Cima M.J. Multimechanism oral dosage forms fabricated by three dimensional printing. J. Control. Release 2000; 66(1)11–17
   PubMed Web of Science ®Google Scholar
• Lin S., Chao P., Chien Y.W., Sayani A., Kumar S., Mason M., West T., Yang A., Monkhouse D.C. In vitro and in vivo evaluations of biodegradable implants for hormone replacement therapy: effect of system design and PK-PD relationship. AAPS Pharm. Sci. Tech. 2001; 2(3), Article 16
   Google Scholar
• Yoo J., Kumar S., Rowe C.W., Monkhouse D.C., Shanahan G., Kang A. Factors influencing the dispersion of rapidly dissolving oral dosage forms fabricated by the TheriForm™ process. AAPS Pharm. Sci. 1999; 1(1), 1998 AAPS Annual Meeting Supplement
   Google Scholar
• Rowe C.W., Wang C., Monkhouse D. TheriForm technology. Modified-Release Drug Delivery Technology, M.J. Rathbone, J. Hadgraft, M.S. Roberts. Marcel Dekker, Inc. 2002; 77–87
   Google Scholar
• Yoo J., Kumar S., Monkhouse D. Dosage Form Exhibiting Rapid Disperse Properties, Methods of Use and Process for the Manufacture of Same. US Patent 6,471,992, October 29, 2002
   Google Scholar
• Pereira C.M., Tam Y.K. Simplified determination of captopril in plasma by high performance liquid chromatography. J. Chromatogr. 1988; 425: 208–213
   PubMed Web of Science ®Google Scholar
• Tsai T., San Y.P., Ho H.S., Wu J.S., Sheu M.T. Film-forming polymer-granulated excipients as the matrix materials for controlled release dosage form. J. Control. Release 1998; 51(2–3)289–299
   PubMed Web of Science ®Google Scholar
• Draper N.R., Smith H. Selecting the best regression equation. Applied Regression Analysis, 2nd Ed. Wiley, New York 1981; 225–311
   Google Scholar
• Seta Y., Higuchi F., Kawahar Y., Nishimura K., Okada R. Design and preparation of captopril sustained-release dosage forms and their biopharmaceutical properties. Int. J. Pharm. 1988; 29: 245–254
   Web of Science ®Google Scholar
• Allen L.V., Erickson M.A. Stability of baclofen, captopril, diltiazem hydrochloride, dipyramide, and flecainide acetate in extemporaneously compounded oral liquids. Am. J. Health-Syst. Ph. 1996; 53(18)2179–2184
   PubMed Web of Science ®Google Scholar
• Yoo J. Comprehensive report on the development and process scale up of pseudoephedrine HCl TheriFlash™ dosage form. Internal Communications, Therics, Inc. 1999, On file
   Google Scholar